Citadel Advisors
TCBPW

Citadel Advisors’s TC BioPharm (Holdings) plc Warrants TCBPW Stock Holding History

Citadel Advisors’s Portfolio TCBPW Stock Details TCBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,178
Closed -$257 – 15498
2024
Q2 		$257 Buy
+19,178
New +$320 ﹤0.01% 14052

Other funds holding TCBPW

KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's TCBPW Position: Q3 2024 in Review

Citadel Advisors sold out of TC BioPharm (Holdings) plc Warrants (TCBPW) in Q3 2024, closing a stake of 19,178 shares — an estimated $257 sold.

Citadel Advisors first reported a position in TCBPW in Q2 2024 and held it in 1 quarter. The position peaked at $257 in Q2 2024. 6 funds tracked by Wall St. Rank hold TCBPW as of Q3 2024.

  • Citadel Advisors reported no remaining TC BioPharm (Holdings) plc Warrants position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 19,178 TC BioPharm (Holdings) plc Warrants shares in Q3 2024, an estimated $257.
  • Citadel Advisors first reported a position in TC BioPharm (Holdings) plc Warrants in Q2 2024 and held it in 1 quarter.
  • Citadel Advisors's TC BioPharm (Holdings) plc Warrants position peaked at $257 in Q2 2024.
  • 6 funds tracked by Wall St. Rank held TC BioPharm (Holdings) plc Warrants as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.